American Made Pharmaceuticals Act of 2024
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The American Made Pharmaceuticals Act of 2024 is a legislative proposal introduced in the 118th Congress aimed at addressing issues related to the production of pharmaceuticals within the United States. While the official summary and full text of the bill are not available, the bill's title suggests a focus on promoting or supporting the domestic manufacturing of pharmaceuticals. The bill was referred to the Subcommittee on Health on December 17, 2024, but ultimately failed or expired without further action.
This bill sought to influence the pharmaceutical manufacturing sector in the U.S. but did not advance beyond subcommittee referral and expired without passage.
- The bill is titled the American Made Pharmaceuticals Act of 2024, indicating a focus on domestic pharmaceutical production.
- It was introduced in the House of Representatives during the 118th Congress.
- The bill was referred to the Subcommittee on Health on December 17, 2024, but did not progress further and is now listed as failed or expired.
['Domestic pharmaceutical manufacturers', 'U.S. healthcare sector', 'Potentially patients relying on pharmaceuticals produced in the U.S.']
['Lack of available text limits understanding of implementation mechanisms and funding sources.', 'Without detailed provisions, oversight and enforcement structures are unclear.', 'Potential cost implications for government or industry are unknown.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and is recorded as failed or expired. No further legislative actions were taken as of December 19, 2024.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential stimulation of domestic pharmaceutical manufacturing capacity if implemented.', 'Possible impacts on pharmaceutical supply chains and related industries.', 'Changes in healthcare costs or availability of certain medications depending on bill provisions.']
The absence of both the full bill text and an official summary limits transparency and public understanding of the bill's specific provisions and intended effects. This lack of information poses challenges for oversight and informed legislative debate. The bill's failure to advance beyond subcommittee referral further restricts available data on its potential impact.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.